Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2

Assay and Drug Development Technologies

Volumn 8, Issue 4, 2010, Pages 437-458

  Johnston, Paul A ^a   Dudgeon, Drew D ^a   Shinde, Sunita N ^a   Shun, Tong Ying ^a   Lazo, John S ^a   Strock, Christopher J ^b   Giuliano, Kenneth A ^b   Taylor, D Lansing ^b   Johnston, Patricia A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Cellumen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ATM PROTEIN; CAMPTOTHECIN; CHECKPOINT KINASE 2; CHIMERIC PROTEIN; DOUBLE STRANDED DNA; ELLIPTICINE; GREEN FLUORESCENT PROTEIN; MITOXANTRONE; NUTLIN 3; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BIOSENSOR; CELLULAR DISTRIBUTION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; DNA DAMAGE; HIGH CONTENT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMAGE ANALYSIS; IMAGE PROCESSING; MIXED INFECTION; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SCREENING; VIRUS RECOMBINANT;

ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; CAMPTOTHECIN; CELL LINE, TUMOR; ELLIPTICINES; GENES, P53; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMIDAZOLES; MITOXANTRONE; PIPERAZINES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT FUSION PROTEINS; SMALL MOLECULE LIBRARIES; SPECTROMETRY, FLUORESCENCE; TOPOTECAN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956417772     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0281     Document Type: Article

References (57)

1. Colas P: High-throughput screening assays to discover small-molecule inhibitors of protein interactions. Curr Drug Discov Technol 2008;5:190-199.
2. Lalonde S, Ehrhardt DW, Loqué D, Chen J, Rhee SY, Frommer WB: Molecular and cellular approaches for the detection of protein-protein interactions: latest techniques and current limitations. Plant J 2008;53:610-635.
3. Pagliaro L, Felding J, Audouze K, Nielsen SJ, Terry RB, Krog-Jensen C, Butcher S: Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004;8:442-449.
4. Cummings M, Farnum MA, Nelen MI: Universal screening methods and applications of ThermoFluor. J Biomol Screen 2006;11:854-863.
5. Lievens S, Lemmens I, Tavernier J: Mammalian two-hybrids come of age. Trends Biochem Sci 2009;34:579-588.
6. Angers S, Salahpour A, Bouvier M: Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 2002;42:409-435.
7. Giuliano K, Taylor DL: Fluorescent-protein biosensors: new tools for drug discovery. Trends Biotechnol 1998;16:135-140.
8. Giuliano K, Chen Y, Haskins JR: Fluorescent protein biosensors. Mod Drug Discov 20038:33-37.
9. Giuliano K, Premkumar D, Taylor DL: Optimal characteristics of protein-protein interaction biosensors for cellular systems biology profiling. In: High Content Screening; Science, Techniques and Applications (Haney S, ed.). John Wiley and Sons, Inc., Hoboken, NJ, 2007, 371-387.
10. Kerpoola T: Visualization of molecular interactions by fluorescence complementation. Nat Rev Mol Cell Biol 2006;7:449-456.
11. Li I, Pham E, Truong K: Protein biosensors based on the principle of fluorescence resonance energy transfer for monitoring cellular dynamics. Biotechnol Lett 2006;28:1971-1982.
12. Lundholt BK, Heydorn A, Bjorn SP, Praestegaard M: A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions. Assay Drug Dev Technol 2006;4:679-688.
13. MacDonald M, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK: Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat Chem Biol 2006;2:329-337.
14. Michnick S, Ear PH, Manderson EN, Remy I, Stefan E: Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat Rev Drug Discov 2007;6:569-582.
15. Aylon YaO M: Living with p53, dying with p53. Cell 2007;130:597-600.
16. Chipuk JE, Green DR: Dissecting p53-dependent apoptosis. Cell Death Differ 2006;13:994-1002.
17. Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature 2004;432:316-323.
18. Laureline R, Gilles G, Roux P: Control of cell migration: a tumor supressor function for p53. Biol Cell 2006;98:141-152.
19. Sengupta S, Harris CC: p53: Traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55.
20. Teodoro JG, Evans SK, Green MR: Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 2007;85:1175-1186.
21. Voglestein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000;408:307-310.
22. Wiman KG: Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006;13:921-926.
23. Hu B, Gilkes DM, Chen J: Efficient p53 Activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 2007;67:8810-8817.
24. Hu BGD, Farooqi B, Sebti SM, Chen J: MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006;281:33030-33035.
25. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR: Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 2002;323:491-501.
26. Toledo F, Wahl GM: MDM2 and MDM4:p53 regulators as targets of anticancer therapy. Int J Biochem Cell Biol 2007;39:1476-1482.
27. Wade MWE, Tang M, Stommel JM, Wahl GM: Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006;281:33036-33044.
28. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-1132.
29. Kussie PH, Gorina S, Marechal V, et al.: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996;274:948-953.
30. Vassilev LT: p53 Activation by small molecules: application in oncology. J Med Chem 2005;48:4491-4499.
31. Vassilev LT, Vu BT, Graves B, et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848.
32. Demma MJ, Wong S, Maxwell E, Dasmahapatra B: CP-31398 restores DNAbinding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 2004;279:45887-45896.
33. Foster BA, Coffey HA, Morin MJ, Rastinejad F: Pharmacological rescue of mutant p53 conformation and function. Science 1999;286:2507-2510.
34. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR: Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002;21:2119-2129.
35. Wang W, Wafik SE: Restoration of p53 to limit tumor cell growth. Curr Opin Oncol 2008;20:90-96.
36. Wang W, Ho WC, Dicker DT, et al.: Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 2005;4:893-898.
37. Wang W, Takimoto R, Rastinejad F, El-Deiry WS: Stabilization of p53 by CP- 31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol 2003;23:2171-2181.
38. Johnston P, Foster CA, Shun TY, Skoko JJ, Shinde S, Wipf P, Lazo JS: Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol 2007;5:319-332.
39. Johnston P, Soares KM, Shinde SN, Foster CA, Shun TY, Takyi HK, Wipf P, Lazo JS: Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol 2008;6:505-518.
40. Johnston PA, Phillips J, Shun TY, et al.: HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile Virus. Assay Drug Dev Technol 2007;5:737-750.
41. Johnston PAFC, Tierno MB, Shun TY, Brummond KM, Wipf P, Lazo JS: Characterization of the Cdc25B dual specificity phosphatase inhibitor hits identified in a high throughput screen of the NIH compound library. Assay Drug Dev Technol 2009;7:250-265.
42. Nickischer D, Laethem C, Trask OJ Jr., et al.: Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2- EGFP translocation, c-Jun, and ERK activation. Methods Enzymol 2006;414: 389-418.
43. Trask OJ Jr., Baker A, Williams RG, et al.: Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform. Methods Enzymol 2006;414:419-439.
44. Williams RG, Kandasamy R, Nickischer D, et al.: Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol 2006; 414:364-389.
45. Tovar CRJ, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006;103:1888-1893.
46. Gough AH, Johnston PA: Requirements, features and performance of high content screening platforms, in high content screening: a powerful approach to systems cell biology and drug discovery. Methods Mol Biol 2006;356:41-61.
47. Johnston P: Automated high content screening microscopy. In: High Content Screening (Haney S, ed.). John Wiley and Sons, Inc., Hoboken, NJ, 2008, 25-42.
48. Tierno MBJP, Foster C, Skoko JJ, Shinde SN, Shun TY, Lazo JS: Development and optimization of high-throughput in vitro protein phosphatase screening assays. Nat Protoc 2007;2:1134-1144.
49. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
50. Kurose A, Tanaka T, Huang X, Halicka HD, Traganos F, Dai W, Darzynkiewicz Z: Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis. Cytometry A 2005;68:1-9.
51. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L: Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
52. Zhao H, Traganos F, Darzynkiewicz Z: Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle 2008;7:3048-3055.
53. Peng YLC, Chen L, Sebti S, Chen J: Rescue of mutant p53 transcription function by ellipticine. Ongcogene 2003;22:4478-4487.
54. Shi LMMT, Fan Y, O'Connor PM, Paull KD, Friend SH, Weinstein JN: Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol Pharmacol 1998;53:241-251.
55. Xu G, Mawji IA, Macrae CJ, Koch CA, Datti A, Wrana JL, Dennis JW, Schimmer AD: A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis 2008;13:413-422.
56. Takeba Y, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, Yanagida Y, Kobayashi S: Irinotecan activates p53 with its active metabolite, resulting in human hepatocellular carcinoma apoptosis. J Pharmacol Sci 2007;104:232-242.
57. Zhang C, Zhu H, Yang X, Lou J, Zhu D, Lu W, He Q, Yang B: P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549. J Cancer Res Clin Oncol 2010;136:437-445.